Literature DB >> 27479247

Glucagon-like Peptide 1 Drugs as Second-line Therapy for Type 2 Diabetes.

Peter C Butler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27479247      PMCID： PMC5118084          DOI： 10.1001/jamainternmed.2016.1523

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  10 in total

Review 1.  The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern.

Authors:  C J Currie; J A Johnson
Journal:  Diabetes Obes Metab       Date:  2011-11-21       Impact factor: 6.577

Review 2.  The safety of incretin-based therapies--review of the scientific evidence.

Authors:  Daniel J Drucker; Steven I Sherman; Richard M Bergenstal; John B Buse
Journal:  J Clin Endocrinol Metab       Date:  2011-07       Impact factor: 5.958

3.  Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials.

Authors:  A S Abbas; H-M Dehbi; K K Ray
Journal:  Diabetes Obes Metab       Date:  2015-12-23       Impact factor: 6.577

4.  Activation of the developmental pathway neurogenin-3/microRNA-7a regulates cholangiocyte proliferation in response to injury.

Authors:  Marco Marzioni; Laura Agostinelli; Cinzia Candelaresi; Stefania Saccomanno; Samuele De Minicis; Luca Maroni; Eleonora Mingarelli; Chiara Rychlicki; Luciano Trozzi; Jesus M Banales; Antonio Benedetti; Gianluca Svegliati Baroni
Journal:  Hepatology       Date:  2014-08-25       Impact factor: 17.425

5.  National prevalence, causes, and risk factors for bariatric surgery readmissions.

Authors:  Trit Garg; Ulysses Rosas; Homero Rivas; Dan Azagury; John M Morton
Journal:  Am J Surg       Date:  2016-03-19       Impact factor: 2.565

6.  Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.

Authors:  Jutta Keller; Michael E Trautmann; Harry Haber; Lai San Tham; Tamsin Hunt; Kenneth Mace; Helle Linnebjerg
Journal:  Regul Pept       Date:  2012-09-06

7.  Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.

Authors:  Laurent Azoulay; Kristian B Filion; Robert W Platt; Matthew Dahl; Colin R Dormuth; Kristin K Clemens; Madeleine Durand; Nianping Hu; David N Juurlink; J Michael Paterson; Laura E Targownik; Tanvir C Turin; Pierre Ernst; Samy Suissa; Colin R Dormuth; Brenda R Hemmelgarn; Gary F Teare; Patricia Caetano; Dan Chateau; David A Henry; J Michael Paterson; Jacques LeLorier; Adrian R Levy; Pierre Ernst; Robert W Platt; Ingrid S Sketris
Journal:  JAMA Intern Med       Date:  2016-10-01       Impact factor: 21.873

8.  Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.

Authors:  Jean-Luc Faillie; Oriana H Yu; Hui Yin; Dominique Hillaire-Buys; Alan Barkun; Laurent Azoulay
Journal:  JAMA Intern Med       Date:  2016-10-01       Impact factor: 21.873

9.  A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

Authors:  Peter C Butler; Michael Elashoff; Robert Elashoff; Edwin A M Gale
Journal:  Diabetes Care       Date:  2013-05-03       Impact factor: 19.112

10.  Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.

Authors:  Laurent Azoulay; Kristian B Filion; Robert W Platt; Matthew Dahl; Colin R Dormuth; Kristin K Clemens; Madeleine Durand; David N Juurlink; Laura E Targownik; Tanvir C Turin; J Michael Paterson; Pierre Ernst
Journal:  BMJ       Date:  2016-02-17
  10 in total
  1 in total

Review 1.  Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?

Authors:  George Grunberger
Journal:  Curr Diab Rep       Date:  2017-04       Impact factor: 4.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.